Oxford, UK – 08 October 2013. OGT, a provider of innovative genetics research and biomarker solutions to advance molecular medicine, has won the Best Medtech Dealmaker award at the 2013 Oxford Bioscience Network (OBN) awards held on Wednesday 2 October. The award recognises OGT’s collaboration with the Birmingham and Salisbury NHS Regional Genetics Laboratories to develop and launch a 58-gene solid tumour profiling service to advance vital research into personalised cancer care.
The panel, which includes important genes in breast, prostate, ovarian, lung and colorectal cancers, was developed in partnership with research teams at the centres in Birmingham and Salisbury as part of a £1.16 million funding award from the UK Government-backed Technology Strategy Board’s Stratified Medicines programme. The NHS teams played a key part in the development of the service, validating the tumour profiling assay across different sample types.
Dr Jon Rees, CEO, Oxford Bioscience Network said: “The nature of the collaboration between OGT and Birmingham and Salisbury NHS Regional Genetics Laboratories was of great interest to the OBN Advisory Board, especially as a reflection of the current momentum in healthcare partnerships. The launch of the service in May is testament to how a collaboration of this type can succeed.”
Tim Hall, CFO, who accepted the award for OGT, said, “We value our partnership with the Birmingham and Salisbury NHS Regional Genetics Laboratories very highly. We are pleased that the OBN advisory board recognised the benefits that collaborations between research and industry can bring in the development of ground-breaking medical technologies.”
OGT’s SureSeq™ Solid Tumour Panel Sequencing Service was launched in May 2013, enabling researchers to identify both known and new mutations to develop informed, personalised cancer treatment strategies. OGT is continuing its work with the research teams in Birmingham and Salisbury to develop the solid tumour profiling assay as a product for launch in early 2014.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.Read
In the workshop users will explain how OGT’s SureSeq™ NGS panels can increase throughput and save time and cost in the detection of a wide variety of aberrations.Read